Acquired resistance to anti-EGFR antibodies in metastatic colorectal cancer

doi:10.3760/cma.j.issn.1673-422X.2014.05.012

Abstract

Abstract: The combination of chemotherapy with antiepidermal growth factor receptor antibodies such as cetuximab and panitumumab which prolong the survival time in the past few years have been widely adopted for the treatment of metastatic colorectal cancer. However, a large number of patients develop resistance to these agents, while there is no standard treatment after acquired resistance yet. Therefore, finding out the mechanisms of acquired drug resistance and putting forward reasonable methods to overcome the acquired resistance will be improve its curative effect.

Key words: Colorectal neoplasms, Receptor, epidermal growth factor, Antibodies, monoclonal, Drug resistance

Li Minmin, Bi Xiang, Wang Zhehai. Acquired resistance to anti-EGFR antibodies in metastatic colorectal cancer[J]. Journal of International Oncology, 2014, 41(5): 357-360.

References

［1］ Bardelli A, Jnne PA. The road to resistence: EGFR mutation and cetuximab［J］. Nat Med, 2012, 18(2):199-200. ［2］ Montagut C, Dalmases A, Bellosillo B, et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistence in colorectal cancer［J］. Nat Med, 2012, 18(2):221-223. ［3］ Wheeler DL, Huang S, Kruser TJ, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members［J］. Oncogene, 2008, 27(28):3944-3956. ［4］ Lu Y, Li X, liang K, et al. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistence escaping treatment by the antiEGFR monoclonal antibody cetuximab［J］. Cancer Res, 2007, 67(17):8240-8247. ［5］ Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to antiEGFR therapy in colorectal cancer［J］. Nature, 2012, 486(7404):532-536. ［6］ Diaz LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquiredresistance to targeted EGFR blockade in colorectal cancers［J］. Nature, 2012, 486(7404):537-540. ［7］ Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab［J］. Cancer Biol Ther, 2011, 11(9):777792. ［8］ Ciardiello F, Bianco R, Caputo R. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor,in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy［J］. Clin Cancer Res, 2004, 10(2):784-793. ［9］ Vallbhmer D, Zhang W, Gordon M, et al. Molecular determinants of cetuximab efficacy［J］. J Clin Oncol, 2005, 23(15):3536-3544. ［10］ Li C, Iida M, Dunn EF, et al. Nuclear EGFR contributes to acquired resistence to cetuximab［J］. Oncogene, 2009, 28(43):3801-3813. ［11］ OliverasFerraros C, Massaguer VallLlovera A, Carrion Salip D, et al. Evolution of the predictive markers amphiregulin and epiregulin mRNA during long term cetuximab treatment of KRAS wild type tumor cells［J］. Invest New Drugs, 2012, 30(2):846-852. ［12］ Kim SM, Kim JS, Kim JH, et al. Acquired resistance to cetuximab is mediated by increased PTEN instability and lead crossresistance to gefitinib in HCC827 NSCLC cells［J］. Cancer Lett, 2010, 296(2):150159. ［13］ Wheeler DL, Lida M, Kruser TJ, et al. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab［J］. Cancer Biol Ther, 2009, 8(8):696-703. ［14］ Santini D, Vincenzi B, Addeo R, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?［J］. Ann Oncol, 2012, 23(9):2313-2318. ［15］ Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase Ⅲ trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer［J］. J Clin Oncol, 2008, 26(14):2311-2319. ［16］ Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer［J］. N Engl J Med, 2004, 351(4):337-334. ［17］ Matar P, Rojo F, Cassia R. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMGC225): superiority over singleagent receptor targeting［J］. Clin Cancer Res, 2004, 10(19):6487-6501. ［18］ Dunn EF, Iida M, Myers RA, et al. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab［J］. Oncogene, 2011, 30(5):561-574. ［19］ Garrett JT, Arteaga CL. Resistance to HER2directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications［J］. Cancer Biol Ther, 2011,11(9):793-800. ［20］ Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international,multicentre, randomised, placebocontrolled, phase 3 trial［J］. Lancet, 2013, 381(9863):303-312.

[1]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[4]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[5]	Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer [J]. Journal of International Oncology, 2024, 51(3): 186-190.
[6]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[7]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.
[8]	An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui. Research progress of Nrf2 in ovarian cancer [J]. Journal of International Oncology, 2023, 50(8): 493-497.
[9]	Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356.
[10]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing. Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer [J]. Journal of International Oncology, 2023, 50(5): 268-273.
[11]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun. Construction of postoperative prognosis model for patients with colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 157-163.
[12]	Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 186-190.
[13]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng. Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer [J]. Journal of International Oncology, 2023, 50(12): 717-722.
[14]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu. Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer [J]. Journal of International Oncology, 2023, 50(11): 683-687.
[15]	Liu Xiaojie, Huang Junxing. Research progress of NADPH oxidase 2 in malignant tumors [J]. Journal of International Oncology, 2023, 50(10): 618-621.